Evaluating the presence of SARS-CoV-2 RNA in the pleural fluid of patients undergoing pleural procedures without symptoms of COVID-19
E. Bedawi (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom), M. Fisher (Oxford, United Kingdom), Y. Zhao (Oxford, United Kingdom), V. George (Oxford, United Kingdom), A. Sundaralingam (Oxford, United Kingdom), X. Yao (Oxford, United Kingdom), A. Gondrand (Oxford, United Kingdom), M. Ellayeh (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), J. Thiboutot (Maryland, United States of America), C. Macrosty (North Carolina, United States of America), H. Lee (Maryland, United States of America), J. Akulian (North Carolina, United States of America), L. Yarmus (Maryland, United States of America), D. Feller-Kopman (Maryland, United States of America), T. Dong (Oxford, United Kingdom), J. Wrightson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom)
Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Bedawi (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom), M. Fisher (Oxford, United Kingdom), Y. Zhao (Oxford, United Kingdom), V. George (Oxford, United Kingdom), A. Sundaralingam (Oxford, United Kingdom), X. Yao (Oxford, United Kingdom), A. Gondrand (Oxford, United Kingdom), M. Ellayeh (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), J. Thiboutot (Maryland, United States of America), C. Macrosty (North Carolina, United States of America), H. Lee (Maryland, United States of America), J. Akulian (North Carolina, United States of America), L. Yarmus (Maryland, United States of America), D. Feller-Kopman (Maryland, United States of America), T. Dong (Oxford, United Kingdom), J. Wrightson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom). Evaluating the presence of SARS-CoV-2 RNA in the pleural fluid of patients undergoing pleural procedures without symptoms of COVID-19. 3104
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Mortality among patients with pleural effusion undergoing thoracentesis Source: Eur Respir J 2015; 46: 495-502 Year: 2015
The necessity of examination of patients with pleural effusions by oncological programme Source: Eur Respir J 2006; 28: Suppl. 50, 75s Year: 2006
Evaluation of patients with pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 247s Year: 2004
Impact of indwelling pleural catheter on quality of life in management of malignant pleural effusion in patients with advanced malignancies Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012
Blind pleural biopsy in the study of undiagnosed pleural effusion: results and complications Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema Year: 2020
Surgical problems with the malignant pleural space Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis Year: 2006
Complete and early drainage of exudates may be of clinical benefit in patients with loculated and/or free-flowing tuberculous pleurisy Source: Breathe 2009; 5: 359 Year: 2009
Evaluation of concomitant pleural effusions in patients with lung cancers Source: Eur Respir J 2007; 30: Suppl. 51, 668s Year: 2007
Does blind percutaneous pleural biopsy have a role in the investigation of pleural effusion? A pooled analysis Source: Annual Congress 2009 - Pleural diseases Year: 2009
Are patients with malignant pleural effusions being referred appropriately for surgical intervention? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Is it important to determine pleural fluid amylase in patients with malignant pleural effusions? Source: Eur Respir J 2007; 30: Suppl. 51, 565s Year: 2007
Correlation between pleural fluid and serum C-reactive protein in patients with pleural effusion due to different etiologies Source: Virtual Congress 2020 – Interesting clinical problems for the respiratory physician Year: 2020
Does pleural fluid sample size matter in the cytopathological assessment of unilateral pleural effusion? Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
Diaphragm ultrasound examination before and after fluid drainage in patients with malignant pleural effusion Source: Virtual Congress 2020 – Transthoracic and endobronchial ultrasound Year: 2020
Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004
Predictors of trapped lung in patients with malignant pleural effusions; comparison of pleural elastance and pleural fluid pH Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
Impact of sarcopenia in long-term symptoms in patients with malignant pleural effusion. Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease Year: 2021
Can pleural biopsy histology in combination with pleural fluid adenosine deaminase be used for diagnoses of pleural TB? Source: Virtual Congress 2020 – The young, the old and extrapulmonary tuberculosis Year: 2020
Critical issues in pleural fluid examinations: laboratory parameters, tumour markers and cytological methods Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=110 Year: 2002
Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy Source: Annual Congress 2011 - From outside to inside: access to the pleura Year: 2011